Literature DB >> 29923124

Severe acyclovir-resistant herpes simplex virus 1 infection following cord blood transplantation.

Tomonari Shigemura1, Yozo Nakazawa2, Tomoki Yoshikawa3, Hikaru Fujii3, Souichi Yamada3, Masayuki Saijo3, Ryuhei Okuyama4.   

Abstract

Entities:  

Keywords:  Acyclovir-resistant herpes simplex virus 1; Cord blood transplantation; Foscarnet; Skin lesion

Mesh：

Substances：

Year:  2018        PMID： 29923124     DOI： 10.1007/s12185-018-2480-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  2 in total

1.  Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance.

Authors:  Susanne Schmidt; Kathrin Bohn-Wippert; Peter Schlattmann; Roland Zell; Andreas Sauerbrei
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

2.  Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation.

Authors:  Koji Kawamura; Jin Hayakawa; Yu Akahoshi; Naonori Harada; Hirofumi Nakano; Kazuaki Kameda; Tomotaka Ugai; Hidenori Wada; Ryoko Yamasaki; Yuko Ishihara; Kana Sakamoto; Masahiro Ashizawa; Miki Sato; Kiriko Terasako-Saito; Shun-Ichi Kimura; Misato Kikuchi; Hideki Nakasone; Rie Yamazaki; Junya Kanda; Shinichi Kako; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2015-05-20       Impact factor: 2.319
  2 in total
  1 in total

1.  Efficacy of Pleuran (β-Glucan from Pleurotus ostreatus) in the Management of Herpes Simplex Virus Type 1 Infection.

Authors:  Ingrid Urbancikova; Dana Hudackova; Juraj Majtan; Zuzana Rennerova; Peter Banovcin; Milos Jesenak
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-13       Impact factor: 2.629
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.